Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound) that has demonstrated superior weight loss and glycemic control compared to semaglutide. It activates both incretin pathways simultaneously, producing enhanced metabolic effects.
Evidence Summary
Tirzepatide is among the most effective incretin therapies studied. In SURMOUNT-5 (New England Journal of Medicine, 2025; 751 adults with obesity but without type 2 diabetes, 72 weeks), the first head-to-head trial against semaglutide, tirzepatide produced a mean body-weight reduction of 20.2% (95% CI -21.4 to -19.1) versus 13.7% (95% CI -14.9 to -12.6) with semaglutide (p<0.001), with greater proportions reaching every weight-loss threshold (for example about 48% of tirzepatide-treated adults lost at least 20% of body weight versus about 27% on semaglutide). The SURPASS program showed superior HbA1c reduction in type 2 diabetes, and SURMOUNT-OSA improved obstructive sleep apnea severity. In a three-year analysis of adults with obesity and prediabetes (NEJM, 2024; 176 weeks), 1.3% of tirzepatide-treated adults progressed to type 2 diabetes versus 13.3% on placebo, roughly a 93% lower risk. In the SUMMIT trial (NEJM, 2024/2025; 731 adults with heart failure with preserved ejection fraction and obesity, median 104 weeks), tirzepatide reduced a composite of cardiovascular death or worsening heart-failure events (9.9% vs 15.3%; hazard ratio 0.62, 95% CI 0.41-0.95; p=0.026) and improved the Kansas City Cardiomyopathy Questionnaire score (between-group difference 6.9 points, 95% CI 3.3-10.6). These are approved or investigated metabolic and cardiovascular indications, not an aging indication. A 2026 update: tirzepatide is now being tested against aging endpoints in the UTMB Moody Longevity Trial (adults 55-70, epigenetic-clock and physical-function outcomes, in recruitment as of August 2026), but no results exist yet, the comparator is unblinded observation rather than placebo, and it is powered for biomarker signal rather than clinical outcomes. The only randomised GLP-1 aging-clock result published to date is with semaglutide (about 9% slowing of PCGrimAge pace of aging in a specific HIV-associated lipohypertrophy population, Nature Communications 2026), framed by its authors as an early signal rather than rejuvenation. Nothing here establishes that incretin therapy slows human aging. A clinically important caveat in older adults is lean-mass loss with dual incretin agonism: monitor body composition, protein intake and resistance training. Educational information, not medical advice. UPDATE (November 8, 2026): EARLY / COMMERCIAL SIGNAL - NOT PEER REVIEWED. At ARDD 2026 Eli Lilly presented an unpublished, single-arm epigenetic sub-study of the tirzepatide arm of SURMOUNT-5: 71 participants with paired baseline and week-72 samples, no control arm. All 15 age-unit clocks moved less than the ~1.38 years elapsed, but only two reached statistical significance (median ~0.7 and ~1.1 years); DunedinPACE fell from a median of 1.13 to 1.08. Lilly called the findings preliminary and hypothesis-generating. Short follow-up relative to clock measurement error, discordant clock signals, and the fact that clocks are not clinical outcomes all limit interpretation. A separate analysis argues single-clock intervention results merit confidence only when reliable PC-based, mortality-trained or pace-of-aging, and multiple concordant clocks respond.
Evidence Scale
Mechanism of Action
Dual agonism of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptor activation enhances fat oxidation and energy expenditure in adipose tissue, while GLP-1 reduces appetite and improves insulin secretion. The combined mechanism produces synergistic metabolic improvement beyond single-receptor agonists.
Who Is This For?
BMI ≥30, or BMI ≥27 with comorbidity. Type 2 diabetes inadequately controlled. Patients who have plateaued on GLP-1 monotherapy. Off-label: metabolic optimization.
Protocol & Dosing
Dose
Start 2.5mg weekly for 4 weeks, then escalate: 5mg → 7.5mg → 10mg → 12.5mg → 15mg. Each dose maintained for minimum 4 weeks before escalation. Maximum dose 15mg weekly.
Frequency
Weekly injection
Duration
Ongoing / Long-term
Protocol Summary
Weekly subcutaneous injection with gradual dose escalation over 20+ weeks. Mounjaro indicated for T2D, Zepbound for chronic weight management. Combine with lifestyle modifications and strength training.
Interactions & Precautions
Contraindications
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- Severe gastrointestinal disease
- History of pancreatitis
- Pregnancy
Potential Risks
- •Thyroid C-cell tumor risk (preclinical)
- •Lean mass loss
- •Gallbladder events
- •Potential pancreatitis
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
May offer advantages over semaglutide for patients with significant insulin resistance. Monitor body composition closely — dual agonism may accelerate lean mass loss. GI side effects may be more pronounced during titration. Currently more expensive than semaglutide. Updated September 6, 2026: Expect patients to raise the UTMB Moody Longevity Trial (tirzepatide vs epigenetic clocks and physical function, adults 55-70, in recruitment as of August 2026). Two things to say: results do not exist yet, and the design - unblinded observation comparator, biomarker-powered - means even a positive readout will be hypothesis-generating rather than practice-changing. The clinically important variable to keep watching in this population is unchanged and is not the clock: lean-mass loss with dual incretin agonism in older adults. Continue to monitor body composition, protein intake and resistance training in any patient over 55 on tirzepatide, and do not let an aging-biomarker framing displace sarcopenia risk from the consultation. Updated November 8, 2026: If patients cite the Lilly/Novo ARDD clock data, state plainly that it is unpublished company-presented data, single-arm for tirzepatide (n=71 paired), with only 2 of 15 clocks significant. It is not a basis for an anti-aging indication; body-composition, protein intake and resistance training remain the priority in older adults.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Latest Evidence
2024–2026: head-to-head superiority and the first cardiovascular outcomes
In SURMOUNT-5 (New England Journal of Medicine, 2025), the first head-to-head trial in 751 adults with obesity without diabetes, tirzepatide reduced body weight by 20.2% at 72 weeks versus 13.7% with semaglutide (p<0.001), and more tirzepatide-treated adults reached every weight-loss threshold — for example about 48% lost at least 20% of body weight versus about 27% on semaglutide. The SURPASS program showed greater HbA1c reduction in type 2 diabetes, and SURMOUNT-OSA improved obstructive sleep apnea severity.
Benefits now extend beyond weight. In a three-year analysis of adults with obesity and prediabetes (NEJM, 2024), 1.3% of tirzepatide-treated adults progressed to type 2 diabetes versus 13.3% on placebo — roughly a 93% lower risk. The SUMMIT trial (NEJM, 2024/2025; 731 adults with heart failure with preserved ejection fraction and obesity) reduced a composite of cardiovascular death or worsening heart-failure events (hazard ratio 0.62, 95% CI 0.41–0.95) and improved symptom scores, the first hard cardiovascular-outcome signal for the dual GIP/GLP-1 agonist.
These are summaries of published randomized trials for approved or investigated metabolic and cardiovascular indications, not treatment claims and not an aging indication. In older adults, monitor for lean-mass loss with dual incretin agonism and support it with adequate protein and resistance training. Educational information, not medical advice — discuss any GLP-1-based therapy with a qualified clinician.
Head-to-head RCT · 751 adults · 72 weeks · obesity without type 2 diabetes
SURMOUNT-5: weight-loss responders at 72 weeks
Source: SURMOUNT-5, a 72-week head-to-head RCT in 751 adults with obesity without type 2 diabetes (NEJM, 2025). Mean weight change -20.2% (tirzepatide) vs -13.7% (semaglutide). Values are percent of participants reaching each threshold.
Related on Peak Human
Semaglutide
The GLP-1 benchmark tirzepatide outperformed head-to-head in SURMOUNT-5.
Retatrutide
Investigational triple agonist — the next step beyond dual incretin agonism.
GLP-1 Agonists
Overview of the incretin receptor-agonist class.
Metformin
Foundational metabolic-longevity agent, often sequenced with incretins.
Weight Loss
Goal-based protocols where incretin therapy fits.
Diabetes
Type 2 diabetes and prevention protocols.
Heart Disease
Cardiometabolic and HFpEF risk — the SUMMIT population.
Optimization at Peak Human
Physician-supervised, biomarker-tracked metabolic optimization.
Longevity Research Insider
Weekly review of new longevity research.
Oral GLP-1 (Shop)
Physician-supervised GLP-1 option available through Peak Human.
Key references: Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5) — New England Journal of Medicine (2025) · Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT) — New England Journal of Medicine (2024) · Tirzepatide for obesity treatment and diabetes prevention (3-year SURMOUNT-1) — New England Journal of Medicine (2024)
Cost & Access
Cost Range
$$$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
